Announcement on Voluntary Disclosure of Receiving Drug Clinical Trial Approval Notice for BL-M14D1 for Injection (DLL3 ADC) in Combination Therapy for the Treatment of Extensive-Stage Small Cell Lung Cancer

About this update from Sichuan Biokin Pharmaceutical Co., Ltd. Class A

Announcement on Voluntary Disclosure of Receiving Drug Clinical Trial Approval Notice for BL-M14D1 for Injection (DLL3 ADC) in Combination Therapy for the Treatment of Extensive-Stage Small Cell Lung Cancer The abstract is for reference only. Please refer to the full text of the announcement on the very day. Link of Full Text for Reference: View Attachment

View stock analysis, news, and events for Sichuan Biokin Pharmaceutical Co., Ltd. Class A